Centessa Pharmaceuticals plc (NASDAQ:CNTA) Short Interest Down 7.3% in January

Centessa Pharmaceuticals plc (NASDAQ:CNTA) was the recipient of a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 3,050,000 shares, a decline of 7.3% from the January 15th total of 3,290,000 shares. Currently, 3.4% of the company’s stock are short sold. Based on an average daily trading volume, of 678,600 shares, the short-interest ratio is currently 4.5 days.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Guggenheim reissued a “buy” rating on shares of Centessa Pharmaceuticals in a report on Monday, February 10th. TD Cowen assumed coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating for the company. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $25.83.

Centessa Pharmaceuticals Stock Down 4.7 %

Shares of CNTA stock traded down $0.81 during trading hours on Tuesday, hitting $16.26. 1,206,357 shares of the company were exchanged, compared to its average volume of 793,034. The company has a market capitalization of $2.14 billion, a PE ratio of -10.63 and a beta of 1.53. Centessa Pharmaceuticals has a 52 week low of $7.75 and a 52 week high of $19.09. The business has a 50 day moving average of $16.74 and a two-hundred day moving average of $15.78. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15.

Insider Activity at Centessa Pharmaceuticals

In other news, insider Karen M. Anderson sold 30,526 shares of the stock in a transaction on Friday, February 7th. The shares were sold at an average price of $19.03, for a total transaction of $580,909.78. Following the transaction, the insider now owns 54,322 shares in the company, valued at $1,033,747.66. This represents a 35.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Saurabh Saha sold 55,000 shares of the stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.89, for a total transaction of $928,950.00. Following the transaction, the chief executive officer now directly owns 575,661 shares in the company, valued at $9,722,914.29. The trade was a 8.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 452,652 shares of company stock valued at $7,800,532. Company insiders own 11.59% of the company’s stock.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. raised its position in Centessa Pharmaceuticals by 47.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after acquiring an additional 826 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in Centessa Pharmaceuticals by 99.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,593 shares of the company’s stock worth $217,000 after buying an additional 6,785 shares during the last quarter. Atria Investments Inc raised its stake in Centessa Pharmaceuticals by 7.0% in the third quarter. Atria Investments Inc now owns 17,134 shares of the company’s stock valued at $274,000 after buying an additional 1,116 shares during the period. GSA Capital Partners LLP lifted its position in shares of Centessa Pharmaceuticals by 66.1% in the third quarter. GSA Capital Partners LLP now owns 93,658 shares of the company’s stock valued at $1,498,000 after buying an additional 37,275 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Centessa Pharmaceuticals by 88.1% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 264,969 shares of the company’s stock worth $4,237,000 after acquiring an additional 124,075 shares during the last quarter. 82.01% of the stock is owned by institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.